Over the past few years researchers have demonstrated, numerous times, that using senolytic therapies to remove a significant fraction of senescent cells from old tissues in mice can reverse aspects of aging, successfully treat multiple age-related diseases that presently have no viable treatment options, and extend healthy life. In an exciting recent addition to this field of research, scientists used the dasatinib and quercetin combination in mouse models of Alzheimer’s disease. The result is a restoration of function and a reduction of the characteristic tau aggregation that is a feature of this condition. The researchers in fact report that there is a two-way relationship between tau aggregation and cellular senescence: targeting either one reduces the other.
Even allowing for the fact that mouse models of Alzheimer’s are highly artificial, as no such analogous condition naturally occurs in that species, this might be taken as good evidence for senescent cell accumulation to provide a meaningful contribution to neurodegeneration. Further, I think it important to note that the particular senolytics used here are very cheap. Dasatinib is a generic drug with years of human usage data resulting from the treatment of cancer, and can be
Article originally posted at